DeepMed Research

Incyte

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 2.5K

Market Cap: $12.6B

Website

Introduction: Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Clinical Trials

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

Phase 3

Not yet recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Drug: Ruxolitinib Cream
Drug: Vehicle Cream

First Posted Date: 2025-05-06

Last Posted Date: 2025-05-13

Lead Sponsor: Incyte Corporation

Target Recruit Count: 400

Registration Number: NCT06959225

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

Phase 3

Not yet recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Drug: Ruxolitinib Cream
Drug: Vehicle Cream

First Posted Date: 2025-05-06

Last Posted Date: 2025-05-13

Lead Sponsor: Incyte Corporation

Target Recruit Count: 450

Registration Number: NCT06958211

A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: INCB057643

First Posted Date: 2025-04-23

Last Posted Date: 2025-05-02

Lead Sponsor: Incyte Corporation

Target Recruit Count: 48

Registration Number: NCT06941077

Locations: 🇺🇸
Celerion, Inc, Tempe, Arizona, United States

A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis Participants

Not yet recruiting

Conditions: Atopic Dermatitis
Healthy Volunteers

First Posted Date: 2025-04-18

Last Posted Date: 2025-04-24

Lead Sponsor: Incyte Corporation

Target Recruit Count: 20

Registration Number: NCT06934980

An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)

Conditions: Squamous Cell Carcinoma of the Anal Canal

First Posted Date: 2025-04-04

Last Posted Date: 2025-04-16

Lead Sponsor: Incyte Corporation

Registration Number: NCT06910137

A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics of INCB123667 When Administered Orally to Healthy Adult Participants

Phase 1

Not yet recruiting

Conditions: Healthy Participants

Interventions: Drug: INCB123667

First Posted Date: 2025-04-03

Last Posted Date: 2025-04-16

Lead Sponsor: Incyte Corporation

Target Recruit Count: 15

Registration Number: NCT06909162

A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors

Phase 1

Not yet recruiting

Conditions: Solid Tumors
Advanced Solid Tumors
Metastatic Solid Tumors

Interventions: Drug: INCB177054
Drug: Retifanlimab

First Posted Date: 2025-03-13

Last Posted Date: 2025-03-18

Lead Sponsor: Incyte Corporation

Target Recruit Count: 322

Registration Number: NCT06873789

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Phase 3

Recruiting

Conditions: Hidradenitis Suppurativa (HS)

Interventions: Drug: povorcitinib

First Posted Date: 2025-03-03

Last Posted Date: 2025-05-15

Lead Sponsor: Incyte Corporation

Target Recruit Count: 600

Registration Number: NCT06855498

Locations: 🇯🇵
Investigative Site JP008, Nishihara, Japan
🇺🇸
Investigative Site US086, Birmingham, Alabama, United States
🇺🇸
Investigative Site US098, Montgomery, Alabama, United States

and more 313 locations

A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD

Phase 1

Recruiting

Conditions: Chronic Graft-versus-host-disease

Interventions: Drug: INCA034176

First Posted Date: 2025-02-25

Last Posted Date: 2025-05-13

Lead Sponsor: Incyte Corporation

Target Recruit Count: 30

Registration Number: NCT06843408

Locations: 🇨🇳
Peking University People'S Hospital, Beijing, China
🇨🇳
Shanghai Children'S Medical Center, Shanghai, China
🇨🇳
West China Hospital of Sichuan University, Chengdu, China

and more 5 locations

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

Phase 3

Not yet recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: Ruxolitinib
Drug: Vehicle Cream

First Posted Date: 2025-02-18

Last Posted Date: 2025-02-20

Lead Sponsor: Incyte Corporation

Target Recruit Count: 240

Registration Number: NCT06832618

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy